Response to "The unresolved link between MASLD and long-term ferritin dynamics in HCV-cured patients"
Yu-Ping Chang1, Jia-Horng Kao2, Chen-Hua Liu3
1Department of Internal Medicine, National Taiwan University Biomedical Park Hospital, Hsin-Chu, Taiwan.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|December 18, 2025
Abstract
No abstract available in PubMed .
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200


